Picard Medical Rule 10b-5 Lawsuit

Peiffer Wolf is currently investigating Picard Medical for possible violations of Rule 10b-5. The investigation focuses on the company’s alleged failure to disclose material adverse facts concerning its business, operations, and the true nature of the trading activity in its securities.

Picard Medical, Inc. is a publicly traded medical technology company that claims to engage in the design, manufacturing, production, supply, marketing, and sale of medical device products. The company states that one of its most significant products is an artificial heart called the “SynCardia TAH.”

A recent federal court complaint alleges that Picard Medical violated SEC Rule 10b-5, which makes it unlawful to lie, mislead, or omit important information in connection with buying or selling any securities or investment products.

If you invested in Picard Medical securities between September 2, 2025, and October 31, 2025 (the “Class Period”), and suffered losses, Contact Us as soon as possible for a Free Case Evaluation by filling out an online form or by calling 585-310-5140. The deadline to seek appointment as lead plaintiff is currently reported as April 13, 2026.

Picard Medical Stock | Allegations in the Complaint

According to a complaint filed in February 2026, Picard Medical had limited operational success and minimal legitimate revenue prior to the Class Period. Nonetheless, the company’s stock (NYSEAmerican: PMI) allegedly experienced significant trading volume and alleged artificial price increases during this period, which the complaint attributes to promotional activity rather than genuine business performance.

Specifically, the lawsuit alleges that Picard Medical and related defendants allegedly participated in a coordinated “pump-and-dump” scheme. The central allegations include:

• Artificial Stock Promotion – The company allegedly participated in or allowed the dissemination of misleading promotional materials designed to inflate its stock price. These promotions, carried out over social media, allegedly portrayed the company as having strong growth prospects, valuable products, and significant business opportunities that were not supported by the company’s actual operations.

• Failure to Disclose Paid Promotions – The complaint alleges that third parties were compensated to promote the company’s stock on social media and other channels. It is alleged that these payments and the financial relationships behind the promotions were not properly disclosed to investors.

• Material Misrepresentations and Omissions – The defendants allegedly made false and/or misleading statements about the company’s business operations and prospects. The complaint asserts that they failed to disclose key material facts necessary to make public statements not misleading.

• Stock Price Inflation and Investor Harm – According to the complaint, the promotional campaign allegedly caused the compan y’s stock price to rise artificially. The complaint further alleges that the stock price reached an intraday high of approximately $13.68 before later declining when the alleged promotional activity ceased, resulting in financial losses for investors who purchased during the inflated period.

Picard Medical Lawsuit

The complaint asserts that the defendants’ actions violate federal securities laws, specifically:

• Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 – Section 10(b) prohibits the use of any manipulative or deceptive device in connection with the purchase or sale of securities. Disseminating false or misleading information to inflate stock prices, participating in undisclosed stock promotions, and making material misrepresentations or omissions that investors rely upon all violate these provisions, as alleged in the complaint. The complaint further alleges that the defendants violated Rule 10b-5 by promoting the stock without proper disclosure of compensation arrangements and by misstating or omitting key facts about the company’s business.

• Section 20(a) (Control Person Liability) – Section 20(a) provides that individuals who control a company can be held liable for the company’s securities law violations. The complaint alleges that certain executives or controlling persons had the power to influence or direct the company’s actions and are therefore liable for the alleged violations.

FREE Consultation | 585-310-5140

Picard Medical was allegedly involved in a “pump-and-dump” promotion scheme that artificially inflated the company’s stock price through misleading promotional campaigns and nondisclosure of compensation arrangements, in potential violation of federal securities laws. When the alleged inflation dissipated, investors suffered losses.

Peiffer Wolf is currently investigating potential Rule 10b-5 violations involving securities sold to retail investors. If you purchased Picard Medical (NYSEAmerican: PMI) securities between September 2, 2025, and October 31, 2025 and suffered losses, Contact Us for a Free Case Evaluation by filling out an online form or by calling 585-310-5140.